Expression of the EGF family in gastric cancer: Downregulation of HER4 and its activating ligand NRG4

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Nielsen, Trine Ostergaard ^a   Friis Hansen, Lennart ^b   Poulsen, Steen Seier ^c   Federspiel, Birgitte ^c   Sorensen, Boe Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Capital Region   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR HER3; EPIDERMAL GROWTH FACTOR RECEPTOR HER4; NEU DIFFERENTIATION FACTOR; PROTEIN NRG2; PROTEIN NRG3; PROTEIN NRG4; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LIGAND; MESSENGER RNA; NEUREGULIN-4;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TREND STUDY; TUMOR INVASION; UPREGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOWN-REGULATION; EGF FAMILY OF PROTEINS; ERBB RECEPTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; MIDDLE AGED; NEUREGULINS; RECEPTOR, ERBB-4; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84899644754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094606     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
2. Kato M, Asaka M (2010) Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol 40(9): 828-837.
3. Li L, Ying XJ, Sun TT, Yi K, Tian HL, et al. (2012) Overview of methodological quality of systematic reviews about gastric cancer risk and protective factors. Asian Pac J Cancer Prev 13(5): 2069-2079.
4. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58(3): 903-913.
5. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, et al. (1997) A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272(42): 26761-26768.
6. Rio C, Buxbaum JD, Peschon JJ, Corfas G (2000) Tumor necrosis factor-alphaconverting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275(14): 10379-10387.
7. Cheng QC, Tikhomirov O, Zhou W, Carpenter G (2003) Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 278(40): 38421-38427.
8. Ni CY, Murphy MP, Golde TE, Carpenter G (2001) gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294(5549): 2179-2181.
9. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, et al. (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 66(12): 6412-6420.
10. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, et al. (1999) Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18(16): 2607-2615.
11. Warren CM, Landgraf R (2006) Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal 18(7): 923-933.
12. Krall JA, Beyer EM, MacBeath G (2011) High-and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One. 6(1): e15945.
13. Sweeney C, Carraway KL III (2000) Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19(49): 5568-5573.
14. Normanno N, De LA, Bianco C, Strizzi L, Mancino M, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1): 2-16.
15. Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4(1): 19-26.
16. Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15(7): 413-448.
17. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, et al. (2008) Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 13(2): 259-268.
18. Yk W, Cf G, T Y, Z C, Xw Z, et al. (2011) Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet 4(1): 14.
19. De VF, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, et al. (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16 Suppl 2(S29-S34).
20. Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697.
21. Trarbach T, Przyborek M, Schleucher N, Heeger S, Lupfert C, et al. (2013) Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Invest New Drugs 31(3):642-52.
22. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, et al. (2011) A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 22(6): 1367-1373.
23. Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64(15): 5245-5250.
24. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA (2013) Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 39(1): 60-67.
25. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, et al. (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29(22): 3030-3036.
26. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, et al. (2008) High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14(23): 7843-7849.
27. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, et al. (2009) Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 33(10): 2112-2118.
28. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, et al. (2004) Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91(12): 2034-2041.
29. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, et al. (2005) Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99(2): 415-421.
30. Saglam O, Shah V, Worsham M J (2007) Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis. Diagn Mol Pathol 16(4): 218-221.
31. Thybusch-Bernhardt A, Beckmann S, Juhl H (2001) Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig 2(5): 393-400.
32. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, et al. (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5(12): 4164-4174.
33. Lee JC, Wang ST, Chow NH, Yang HB (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8): 1065-1071.
34. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J (1997) Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57(15): 3272-3280.
35. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, et al. (2002) ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8(10): 3054-3064.
36. Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, et al. (2009) Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res 29(1): 229-234.
37. Lo NC, Monteverde M, Riba M, Lattanzio L, Tonissi F, et al. (2010) Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol 37(5): 1219-1228.
38. Shi J, Yao D, Liu W, Wang N, Lv H, et al. (2012) Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci 13(4): 4714-4726.